Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/30356
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAdami, Giovanni-
dc.contributor.authorSaag, Kenneth G.-
dc.contributor.authorChapurlat, Roland D.-
dc.contributor.authorGuanabens, Nuria-
dc.contributor.authorHaugeberg, Glenn-
dc.contributor.authorLems, Willem F.-
dc.contributor.authorMatijevic, Radmila-
dc.contributor.authorPeel, Nicola-
dc.contributor.authorPoddubnyy, Denis-
dc.contributor.authorGEUSENS, Piet-
dc.date.accessioned2020-01-21T14:18:49Z-
dc.date.available2020-01-21T14:18:49Z-
dc.date.issued2019-
dc.date.submitted2020-01-20T08:46:29Z-
dc.identifier.citationTHERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 11 (Art N° UNSP 1759720X19883973)-
dc.identifier.issn1759-720X-
dc.identifier.urihttp://hdl.handle.net/1942/30356-
dc.description.abstractBiologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.rightsCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).-
dc.subject.otherbenefit-risk ratio-
dc.subject.otherbiologics-
dc.subject.otherdenosumab-
dc.subject.otherromosozumab-
dc.titleBalancing benefits and risks in the era of biologics-
dc.typeJournal Contribution-
dc.identifier.volume11-
local.format.pages6-
local.bibliographicCitation.jcatA1-
dc.description.notesAdami, G (reprint author), Univ Verona, Rheumatol Unit, Pz Scuro 10, I-37135 Verona, Italy.-
dc.description.notesadami.g@yahoo.com-
local.publisher.place1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedReview-
local.bibliographicCitation.artnrUNSP 1759720X19883973-
dc.identifier.doi10.1177/1759720X19883973-
dc.identifier.isiWOS:000492881100001-
dc.contributor.orcidPoddubnyy, Denis/0000-0002-4537-6015; Adami,-
dc.contributor.orcidGiovanni/0000-0002-8915-0755-
dc.identifier.eissn1759-7218-
dc.identifier.eissn-
local.provider.typewosris-
local.uhasselt.uhpubyes-
item.validationecoom 2020-
item.accessRightsOpen Access-
item.fullcitationAdami, Giovanni; Saag, Kenneth G.; Chapurlat, Roland D.; Guanabens, Nuria; Haugeberg, Glenn; Lems, Willem F.; Matijevic, Radmila; Peel, Nicola; Poddubnyy, Denis & GEUSENS, Piet (2019) Balancing benefits and risks in the era of biologics. In: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 11 (Art N° UNSP 1759720X19883973).-
item.fulltextWith Fulltext-
item.contributorAdami, Giovanni-
item.contributorSaag, Kenneth G.-
item.contributorChapurlat, Roland D.-
item.contributorGuanabens, Nuria-
item.contributorHaugeberg, Glenn-
item.contributorLems, Willem F.-
item.contributorMatijevic, Radmila-
item.contributorPeel, Nicola-
item.contributorPoddubnyy, Denis-
item.contributorGEUSENS, Piet-
crisitem.journal.issn1759-720X-
crisitem.journal.eissn1759-7218-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1759720x19883973.pdfPublished version187.25 kBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

1
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

7
checked on May 8, 2024

Page view(s)

28
checked on Sep 7, 2022

Download(s)

10
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.